GB-Biosciences Inc.

Overview

GB-Biosciences Inc. is a privately-held biotechnology company specializing in the development of innovative therapies targeting neurological disorders. The company focuses on breakthrough treatments that address unmet medical needs in the field of neuroscience.

Therapeutic areas

API / Drug Master Files

GB-Biosciences Inc. holds 35 active (93 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• WXFM006Active2026-03-02
• WXFMB V3Active2026-03-02
• CHO FEED BIOREACTOR SUPPLEMENTActive2026-01-29
• EX-CELL® ADVANCED CHO FED-BATCH MEDIUMActive2026-01-29
• WXBM004-CActive2025-11-03
• WXBM004Active2025-11-03
• CELL CULTURE MEDIUM CR80025, CHOKO FMAActive2025-10-01
• CELL CULTURE MEDIUM CR80026, CHOKO FMBActive2025-10-01
• CELL CULTURE MEDIUM CR80028, CHOKO STOCK CULTURE MEDIUMActive2025-10-01
• CELL CULTURE MEDIUM CR80027, CHOKO PRODUCTION MEDIUMActive2025-10-01
• PF-207Active2025-04-11
• TS-07Active2025-04-11
• PF-107Active2025-04-11
• PSILOCYBINActive2023-05-18
• EX-CELL CD HEK293 VIRAL VECTOR MEDIUMActive2022-09-07

Showing 15 of 93 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to GB-Biosciences Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.